Saraff V, et al. - The experts undertook this study to assess the role of continuous subcutaneous recombinant parathyroid hormone (rhPTH 1–34) infusion (CSPI) in children with hypoparathyroidism associated with intestinal malabsorption resistant to conventional therapy. For managing hypocalcaemia and hyperphosphataemia among children with hypoparathyroidism associated with intestinal malabsorption, CSPI was found to be a promising and effective treatment option.